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ABSTRACT

Despite the need, there are currently no FDA-approved pharmacological treatments for
methamphetamine use disorders. Cue-induced craving during drug withdrawal remains a
significant contributor to high relapse rates. Thus, understanding the neurobiological
mechanisms of cue-induced drug-seeking behavior is critical. Previous research indicates that the
selective 5-HT2A antagonist M100907 attenuates the acquisition of methamphetamine-induced
conditioned place preference (CPP) in male and female adult rats. The present study examines
the effects of M100907 on expression of methamphetamine-induced drug-seeking behavior using
a biased CPP design in adult male and female Long Evans rats (PND 95-112). During
conditioning, rats were administered either saline or methamphetamine (1 mg/kg/ml, i.p.) and
immediately placed into their initially non-preferred chamber. Rats received either vehicle or
M100907 (0.0025, 0.025, 0.1 mg/kg i.p.) 15 minutes prior to expression testing. We found that
none of the M100907 doses significantly altered the expression of methamphetamine-induced
CPP in male nor female rats.
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1. Introduction
Methamphetamine use continues to impact society, with approximately 1.6 million adults
using methamphetamine every year and 50% of those who use methamphetamine meeting the
diagnostic criteria for methamphetamine use disorder (MUD; Jones, 2020). MUD is a growing
problem that contributes significantly to individual health-related morbidity such as
cardiovascular and renal problems, mental disturbances and psychosis (Jones, 2020; Courtney &
Ray, 2014; Jayanthi et al., 2021). The impact of methamphetamine abuse extends beyond
individual harm, contributing to societal issues including crime, unemployment, and child
neglect (NIDA, 2021). Despite the sharply increasing prevalence of MUD, especially in minority
communities, there are no FDA-approved medications for treating MUDs or reversing drug
overdoses (Han, 2021), highlighting the need for research examining novel pharmacotherapies.
Chronic use of psychostimulants such as methamphetamine results in physical dependence,
leading to a cluster of withdrawal symptoms consisting of sleep and appetite disturbances,
fatigue, depressed mood, irritability, heightened stress reactivity, drug craving and anxiety
(Darke et al., 2008; Zhao, 2021; Sanchez-Ramos, 2015). Due to the unpleasantness of these
withdrawal symptoms, relapse is common, with 61% of abstinent patients relapsing to
methamphetamine use within a year of treatment (Brecht & Herbeck, 2014). Thus, current
literature urges for a combination of psychosocial therapies and pharmacotherapy for alleviation
of withdrawal symptoms (Bhatt et al., 2016).
Recent evidence implicates the serotonin 2A (5-HT2A) receptor subtype in the behavioral
consequences of psychostimulants, therefore making it a promising target for treating
psychostimulant use disorders. Several studies have reported 5-HT2A receptor antagonists
decrease hyperlocomotive effects of cocaine, methamphetamine and 3,4-Methylenedioxy
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methamphetamine (MDMA) in male rats (Bankson & Cunningham, 2002; Bubar &
Cunningham, 2006; Bubar & Cunningham, 2008; Herin et al., 2005). Studies examining cocaine
indicate that administration of non-selective 5-HT2A receptor antagonists depresses cocaine cueinduced reinstatement and blocks acquisition and expression of single-trial cocaine CPP in male
rats (Bubar & Cunningham, 2006; Bubar & Cunningham, 2008). M100907, a selective 5-HT2A
receptor antagonist, has been reported to have more robust effects, with both acquisition and
expression of cocaine-induced CPP blocked via pretreatment with M100907 in male rats (dela
Cruz, 2009). Additionally, M100907 suppresses both cocaine-primed and cue-evoked
reinstatement in the self-administration paradigm in both male rats and non-human primates (Nic
Dhonnchadha et al., 2009; Murnane et al., 2013). These effects likely result from altered
mesolimbic function, as M100907 attenuates cocaine-induced overflow in the caudate nucleus in
non-human primates, thereby reducing mesocortical dopamine release which plays a critical role
in drug- and cue-induced reinstatement (Murnane et al., 2013). M100907 has also been
implicated in modulating nicotine-induced behaviors. One study reported that M100907 reduces
nicotine-primed or cue-induced reinstatement in male rats (Fletcher et al., 2012). Another study
indicated that M100907 significantly reduces the depression-like behavioral effects in male rats
during nicotine withdrawal (Zaniewska et al., 2010). Additionally, M100907 reduces cocaineand amphetamine-induced impulsive actions in male rats (Fletcher et al., 2002). Collectively,
these data ascribe a critical role for 5-HT2A receptors in regulating the behavioral effects of
psychostimulants.
Studies examining methamphetamine specifically report that M100907 attenuates
acquisition of methamphetamine-induced reward in male and female rats in the CPP paradigm
(Madden et al., 2020; 2021) and decreases anxiety-like behavior following chronic

3
methamphetamine exposure in male rats (Madden et al., 2021). Additionally, M100907 dosedependently decreases methamphetamine self-administration and methamphetamine-seeking
behavior in male and female rhesus macaques (Odabas-Geldiay et al., 2019) and male rats
(Graves et al., 2012). Chronic methamphetamine exposure causes dysregulation of 5-HT2A
receptors in the medial prefrontal cortex (PFC) and perirhinal cortex, leading to increases in 5HT2A receptor expression in male rats (Hámor et al., 2018). Additionally, chronic
methamphetamine increases 5-HT2A receptors in the PFC and ventral tegmental area (VTA),
leading to increased levels of dopamine neurons in mesocorticolimbic structures in male rats
(Doherty & Pickel, 2000; Alex & Pehek, 2007). Thus, blocking 5-HT2A with M100907 may
dampen this heighted dopamine signaling, leading to attenuation of drug-seeking behavior and
drug reward (Cunningham et al., 2013; Pehek et al., 2006).
In the present study, we hypothesized that blocking 5-HT2A receptors will dose-dependently
attenuate expression of methamphetamine-induced CPP in both male and female rats. A
substantial proportion of pyramidal neurons in the PFC that project to areas such as the dorsal
raphe and VTA express higher concentrations of 5-HT2A receptors compared to other 5-HT
receptors (Vázquez-Borsetti et al., 2009). These areas are significant for neurological disorders,
such as addiction, because they contain high levels of serotonergic innervation (Mengod et al.,
2015), and activation of these receptors leads to increased mesolimbic dopamine release.
Females exhibit increased 5-HT receptors expression throughout the entire brain, with increased
levels in critical addiction-related structures such as the striatum and cortex (Carlsson &
Carlsson, 1988; Summer & Fink, 1995). However, studies have reported that females have
diminished binding to the postsynaptic 5-HT2A receptors compared to males (Biver et al., 1996;
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Soloff et al., 2010), which likely mitigates these sex differences in the serotonergic system and
diminishes the likelihood that any sex differences would impact the present study.
2. Materials and methods
2.1. Animals
Subjects were adult female and male Long-Evans hooded rats (N=94, Male N=46,
Female N=48; 97-111 days old), born and reared in the Logan Hall facility at the University of
New Mexico. All rats were pair housed in standard home cages (21.6 x 45.7 x 17.8 cm) in a
temperature-controlled colony room (21-24 ◦C) with a reverse 12:12 light/dark cycle (lights off
at 10 am), with food and water available ad libitum in their home cages. Rats were handled for
one week prior to testing. All husbandry and experimental procedures adhere to the Guide for the
Care and Use of Laboratory Animals (National Research Council, 2011) and were approved by
the University of New Mexico Institutional Animal Care and Use Committee.
2.2. Drugs
M100907 (Axon Medchem LLC, Reston, VA, USA) and methamphetamine
hydrochloride (Sigma Aldrich, St. Louis, MO, USA) were dissolved in 0.9% sterile saline and
administered intraperitoneally (i.p.) at a volume of 1 ml/kg of body weight; M100907 also
contained 3% Tween 20 (vehicle). The doses of methamphetamine (0 or 1 mg/kg, i.p.) and
M100907 (0, 0.0025, 0.025, 0.1 mg/kg, i.p.) were selected based on previous research showing
that this methamphetamine dose is effective in producing reliable CPP and that these doses of
M100907 attenuate methamphetamine-induced hyperactivity and acquisition of
methamphetamine-induced CPP (Zakharova et al., 2009; Steed et al., 2011; Madden et al., 2020).
2.2.1 Behavioral testing
2.2.2. Conditioned place preference
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Conditioning was conducted in plexiglass apparatuses each composed of two equal-sized
compartments (25 x 25 x 45 cm). The two conditioning compartments were divided by a
removable solid partition. On habituation, baseline and preference test days the partition was
removed and replaced with a partition that contained a small opening (8 x 8 cm), allowing free
access to both compartments. The two conditioning compartments are distinguishable by color,
odor and texture. Specifically, one compartment consists of a grid flooring, corncob bedding and
white walls while the other compartment consists of bar flooring, pine bedding and black walls.
The first day, designated as habituation, consisted of each rat being placed into the apparatus
and allowed to freely explore both compartments for 15 minutes in order to acclimate to the
novel environment. The time spent in each compartment was not recorded on this day. The next
two days, designated as baseline, were identical except the amount of time the rats spent in each
side of the apparatus was recorded and averaged across the two days in order to determine the
rats’ initially non-preferred side, operationally defined as the compartment in which the rats
spent less than 50% of their total time. Overall, both males and females showed a preference for
the black/bar side compared to the white/grid side (see Tables 1 and 2), suggesting that the
apparatus was biased. However, the means for each non-preferred side were nearly equal and the
experimental groups were counterbalanced for baseline preference across both compartments.
Conditioning occurred over the next four days and consisted of two thirty-minute sessions per
day, with the first session occurring in the morning and the second session occurring four hours
later to allow for drug clearance. This study utilized a biased design where methamphetamine
was paired with the rats’ initially non-preferred side. During the conditioning sessions, rats in all
groups received a saline injection prior to being placed in their preferred side. The order of
saline/methamphetamine injections was counterbalanced each day of conditioning to control for
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potential effects of time of day. On the final day of testing (i.e., expression testing), rats were
administered their assigned dose of M100907 (0.0025, .025, 0.1) or saline 15 minutes prior to
being placed in the CPP box. The amount of time the rats spent on each side was recorded. (See
Figure A for experimental timeline). Throughout all phases of the CPP procedure, a continuous
white noise generator was set at 15 dB above background to minimize ambient noise and
enhance the salience of the environment. All sessions were conducted under red light and all
apparatuses used were promptly wiped down with 5% ethanol after each trial.
Figure A: Timeline

Experimental design and timeline of the 8-day conditioned place preference (CPP) procedure.
The experiment consisted of 1 day of habituation (Hab.), 2 days of baseline preference testing, 4
days of conditioning (8 conditioning sessions total/ 2 a day), 1 expression test trial. The
habituation, baseline, and test were 15 minutes. During baseline days (2-3), rats were allowed to
freely roam the two compartments and initial side preference was recorded. For conditioning
days (4-7), rats received methamphetamine (1.0 mg/kg) on their non-preferred side and saline on
their preferred. Each conditioning session was 30 minutes and occurred twice a day using a
counterbalanced design. One preference testing day (8) occurred following the last day of
conditioning to assess the rats’ final preference.
2.3. Data Analysis
Methamphetamine-induced CPP was operationally defined as a significant increase in
time spent on the initially non-preferred side (i.e., baseline) following conditioning. In order to
ensure there were no strong deviations in initial preference, a one-way ANOVA comparing the
baselines for each group was conducted. To examine the magnitude of M100907 effects on
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methamphetamine-induced CPP, group differences were examined using both difference scores
and percent change from baseline scores. Difference scores were calculated by taking the time
spent in the non-preferred side during the expression test minus the time spent in the nonpreferred side during initial baseline testing. Percent change from baseline scores were calculated
using the formula [(A2-A1)/A1] *100, where A2 represents time spent in the non-preferred side
during the expression test and A1 represents the time spent in the non-preferred side during
baseline testing. In order to verify that the dose of methamphetamine was rewarding (i.e.,
produced CPP), separate independent samples t-tests were run comparing control (Saline-Tween)
and methamphetamine (Meth-Tween) groups on measures of percent change and difference from
baseline (i.e., test – baseline). Within group CPP was also determined for the control (SalineTween) and methamphetamine (Meth-Tween) groups using paired samples t-tests. To examine
the effects of M100907 on expression of methamphetamine-induced CPP, potential differences
in time spent on the drug-paired side on baseline and test day was analyzed using a repeated
measures ANOVA with M100907 dose as the between group variable (Meth-M0.0025, MethM0.025, Meth-M0.1) and baseline and test day as within factors. In order to fully characterize
the effects of each dose of M100907 on expression of methamphetamine-induced CPP, potential
differences in preference on baseline and test day were probed using paired sample t-tests for
each M100907 group (Meth-M0.0025, Meth-M0.025, Meth-M0.1); potential group differences
in percent change were also analyzed using a one-way ANOVA.
3. Results
3.1 Males
Figure 1 depicts methamphetamine-induced CPP in males. A one-way ANOVA
comparing group baselines prior to conditioning was not significant [F (4, 39) =0.492, p=0.741],
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indicating that there were no group differences in the magnitude of their initial baseline
preference (Figure 1). An independent samples t-test examining percent change found that
methamphetamine was rewarding in males (i.e., produced CPP) with the Meth-Tween group
(M= 49.18, SD=21.98) showing a significantly larger percent change (Figure 1B; t(15)= -5.00,
p<.001) compared to Saline-Tween group (M= -3.45, SD= 21.25). Similarly, an independent
samples t-test investigating difference scores (i.e., post-conditioning change in baseline
preference) confirmed that methamphetamine produced CPP with Meth-Tween (M=187,
SD=57.22) rats exhibiting significantly larger difference scores (Figure 1C; t(15)=-5.92, p<.001)
compared to Saline-Tween (M=-16.56, SD= 83.60) rats. Lastly, paired samples t-tests indicated
that the Meth-Tween (t(8)=-9.80, p<.001) group but not the Saline-Tween (t(7)=0.560, p=0.593)
group exhibited a significant preference switch following conditioning.
Figure 2 illustrates the effects of M100907 on expression of methamphetamine-induced
CPP. The repeated measures ANOVA testing the impact of M100907 on methamphetamineinduced CPP (Meth-Tween, Meth-M0.0025, Meth-M0.025, Meth-M0.1) detected a significant
main effect of day (F(1,28) = 160.67, p<0.001), but not a day by M100907 interaction (F(3, 28)
= 1.69, p=0.193). This suggests that M100907 did not alter expression of methamphetamineinduced CPP. To further probe for potential M100907 dose effects, paired samples t-test were
conducted for each M100907 group (Meth-M0.0025, Meth-M0.025, Meth-M0.1). Rats in the
Meth-M0.0025 (t(7)=-5.56, p<.001), Meth-M0.025 (t(7)=-4.22, p=.004) and Meth-M0.1 (t(8)=4.38, p=0.002) groups all showed a significant preference shift following methamphetamine
conditioning. Lastly, we compared percent change and difference scores using a one-way
ANOVA. Neither percent change (Figure 2A; F(3,30)=0.132, p=0.940) nor difference scores
(Figure 2B; F(3,30)=0.049, p=0.985) showed a significant difference between methamphetamine
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groups. Collectively, these data indicate that methamphetamine reliably induced expression of
CPP, but M100907 did not attenuate the rewarding effects of methamphetamine during
expression testing.
Table 1: Male preconditioning baseline preferences

1A

400
300
200
100
0
Saline Meth M.0025 M.025 M.1

60

**

1B

40
20
0

Difference score (s) + SEM

500

% change from baseline + SEM

Time in non-preferred
side (s) + SEM

Non-preferred side
#
Percent of rats
Black Time ± SD
White Time ± SD
Black/Bar
16
36.4%
392.28 ± 39.66
507.5 ± 39.49
White/Grid
28
63.6%
502.64 ± 46.79
397.36 ± 46.79
Total
44
100%
462.51 ± 69.33
437.41 ± 69.22
Baselines were computed as an average of the two pre-conditioning sessions. Bold numbers
indicate the non-preferred compartment. Methamphetamine was paired with the bolded/nonpreferred side of the CPP box during conditioning.

300

1C

**

200
100
0
-100

-20
Saline

Meth

Saline

Meth

Figure 1: Methamphetamine produced robust CPP in males
A one-way ANOVA indicated that rats in each experimental group did not differ in the amount
of time spent in their initially non preferred side prior to methamphetamine (Meth) conditioning
[Figure 1A; F (4, 39) =0.492, p=0.741]. Following conditioning, Meth treated rats showed a
strong conditioned place preference with a significantly larger percent change from baseline
(Figure 1B; t(15)= -5.00, p<.001) and a significantly larger difference score (Figure 1C; t(15)=5.92, p<.001) compared to saline controls. Asterisks (**) represent a significant difference
compared to controls (p<0.001).

80

Difference score (s) + SEM

% Change from baseline + SEM
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2A

60
40
20
0
Meth

M.0025

M.025

M.1

250
2B
200
150
100
50
0
Meth

M.0025

M.025

M.1

Figure 2: Effects of M100907 on methamphetamine in males
M100907 failed to alter expression of methamphetamine (Meth)-induced conditioned place
preference (CPP). Following conditioning, rats received their assigned dose of M100907 (MethTween, Meth-M0.0025, Meth-M0.025, and Meth-M0.1) and then were tested for CPP. All Meth
groups demonstrated a significant preference shift following methamphetamine conditioning
with a one-way ANOVA failing to detect significant group differences in % change from
baseline [Figure 2A; F(3,30)=0.132, p=0.940] or significant difference scores [Figure 2B:
F(3,30)=0.049, p=0.985].
3.1.2 Females
Figure 3 depicts methamphetamine-induced CPP in females. A one-way ANOVA
comparing baselines prior to conditioning was not significant [F (4, 43) = 0.086, p = 0.986],
indicating that there were no group differences in the magnitude of their initial baseline
preference (Figure 3A). An independent samples t-test examining percent change found that the
dose of methamphetamine was rewarding in females (i.e., produced CPP), with the Meth-Tween
group (M= 43.66, SD= 26.16) showing a significantly larger percent change (Figure 3B; t(18)= 2.61, p=0.009) compared to the Saline-Tween group (M= 12.27, SD= 24.55). Similarly, an
independent samples t-test investigating difference scores (i.e., post-conditioning change in
baseline preference) confirmed that methamphetamine produced CPP with Meth-Tween rats
exhibiting significantly larger group differences (Figure 3C; t(18)= -2.81, p= 0.006) compared to
Saline-Tween rats. Lastly, paired samples t-tests indicated that the Meth-Tween (t(12)= -6.39,
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p<0.001) group but not the Saline-Tween (t(6)= -1.22, p=0.134) group exhibited a significant
preference switch following conditioning.
Figure 4 illustrates the effects of M100907 on expression of methamphetamine-induced
CPP. The repeated measures ANOVA testing the effects of M100907 on methamphetamineinduced CPP (Meth-Tween, Meth-M0.0025, Meth-M0.025, Meth-M0.1) detected a significant
main effect of day (F (1,35) =184.60, p<0.001), but not a day by M100907 group interaction
(F(3, 35)=1.12, p=0.354). This suggests that M100907 did not alter expression of
methamphetamine-induced CPP for females. To further probe for potential M100907 dose
effects, paired samples t-tests were conducted for each M100907 group. Rats in the MethM0.0025 (t(7)= -6.88, p<0.001), Meth-M0.025 (t (8)=-5.56, p<0.001) and Meth-M0.1 (t (10)=5.02, p<0.001) groups all showed a significant preference shift following methamphetamine
conditioning. Lastly, we compared percent change and difference scores using a one-way
ANOVA and found no significant differences between methamphetamine groups respectively
(Figure 4A; F(3,35)=0.851, p=0.476); Figure 4B; F(3,35)=1.12, p=0.354). Collectively, these
data indicate that methamphetamine reliably induced expression of methamphetamine-induced
CPP, but M100907 did not attenuate the rewarding effects of methamphetamine in females
during expression testing.
Table 2: Female preconditioning baseline preferences
Non-preferred side
Black/Bar
White/Grid
Total

#
18
30
48

Percent of rats
37.5%
62.5%
100%

Black Time ± SD
418.25 ± 28.22
509.33 ± 40.62
475.18 ± 57.37

White Time ± SD
481.75 ± 28.22
390.67 ± 40.62
424.82 ± 57.37

Baselines were computed as an average of the two pre-conditioning sessions. Bold numbers
indicate the non-preferred compartment. Methamphetamine was paired with the bolded/nonpreferred side of the CPP box during conditioning days.

3A

400
300
200
100
0
Saline Meth M.0025 M.025

60

3B

Difference score (s) + SEM

500

% change from baseline + SEM

Time spent in non-preferred
side (s) + SEM

12

*

40

20

0

M.1

Saline

Meth

250

3C

*

200
150
100
50
0
Saline

Meth

80

Difference score (s) + SEM

% Change from baseline + SEM

Figure 3: Methamphetamine produced robust CPP in females
A one-way ANOVA indicated that rats in each experimental group did not differ in the amount
of time spent in their initially non preferred side prior to methamphetamine (Meth) conditioning
[Figure 3A; [F (4, 43) = 0.086, p = 0.986]. Following conditioning, Meth treated rats showed a
strong conditioned place preference with a significantly larger percent change from baseline
(Figure 3B; t(18)= -2.61, p=0.009) and a significantly larger difference score (Figure 3C; t t(18)=
-2.81, p= 0.006) compared to saline controls. Asterisks (*) represent a significant difference
compared to controls (p<0.05).

4A

60
40
20
0
Meth

M.0025

M.025

M.1

250

4B

200
150
100
50
0
Meth

M.0025 M.025

M.1

Figure 4: Effects of M100907 on methamphetamine in females
M100907 failed to alter expression of methamphetamine (Meth)-induced conditioned place
preference (CPP). Following conditioning, rats received their assigned dose of M100907 (MethTween, Meth-M0.0025, Meth-M0.025, and Meth-M0.1) and then were tested for CPP. All Meth
groups demonstrated a significant preference shift following methamphetamine conditioning
with a one-way ANOVA failing to detect significant group differences in % change from
baseline [Figure 4A; F(3,35)=0.851, p=0.476] or significant difference scores [Figure 4B:
F(3,35)=1.12, p=0.354].
4. Discussion
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Results from the present study indicate that M100907 (0.0025 – 0.1 mg/kg) did not
attenuate expression of methamphetamine-induced CPP. In male rats, there were no significant
differences in baseline preference between groups (Figure 1A), and methamphetamine produced
robust reward (Figure 1B, 1C). In contrast to our hypothesis, administration of M100907 prior to
expression testing did not significantly alter methamphetamine-induced CPP in males (Figure
2A, 2B). Similarly, in females there were no significant group differences in initial baseline
preference (Figure 3A), methamphetamine reliably produced reward (Figure 3B, 3C), and
M100907 did not decrease time spent in the methamphetamine paired side at any of the three
doses of M100907 tested for female rats (Figure 4A, 4B). Although we initially hypothesized
that there would be a dose-dependent effect, none of the M100907 doses significantly altered the
expression of methamphetamine-induced CPP. Collectively, these data along with previous
findings indicate that blocking 5-HT2A receptors with M100907 attenuates acquisition (Madden
et al., 2020; 2021) but not expression of methamphetamine-induced CPP in adult male and
female rats.
One potential reason we failed to detect effects of M100907 on expression of
methamphetamine-induced CPP despite previous research reporting an attenuating effect on
acquisition of methamphetamine-induced CPP (Madden et al., 2020; 2021) could be that
M100907 affects spontaneous locomotion. In the previous reports by Madden and colleagues,
rats did not have methamphetamine or M100907 onboard during expression testing, while in the
current study rats received M100907 injections before expression testing. Although not directly
tested in the present study, previous research suggests that M100907 alters stimulant-induced but
not spontaneous locomotion. For example, M100907 reduces cocaine-induced hyperlocomotion
(0.05 mg/kg; Pockros et al., 2012) and inhibits amphetamine-induced hyperlocomotion without
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affecting spontaneous locomotion (0.1 – 3.0 mg/kg; Moser et al., 1995). Similarly, Zaniewska
and colleagues (0.5-2.0 mg/kg) and McMahon and colleagues (0.02 – 2.0 mg/kg) report that
M100907 does not change spontaneous locomotor activity across a wide range of doses
(Zaniewska et al., 2009; McMahon & Cunningham, 2001). Although the doses in the previous
studies vary slightly, collectively they suggest that the doses of M100907 used in the present
study likely had no impact on spontaneous locomotion and mitigate impaired movement as a
reason for the null effects of M100907 on expression of methamphetamine-induced CPP in the
present study.
Studies examining the effects of M100907 on psychostimulant reinforcement generally
fail to find significant modulatory effects. Indeed, M100907 (0.5-2.0 mg/kg) did not attenuate
cocaine or nicotine self-administration (Fletcher et al., 2002; 2012; Bubar & Cunningham, 2008).
These findings suggest that M100907 fails to alter reinforcement of psychostimulants. However,
two primate studies examining the effects of 5-HT2A antagonism on methamphetamine selfadministration suggest that M100907 may modulate stimulant reinforcement. Banks and
colleagues report that the inverse 5-HT2A receptor agonist Pimavanserin failed to attenuate
methamphetamine reinforcement in rhesus macaques (Banks et al., 2016), while Odabas-Geliday
and colleagues reported that M100907 attenuates methamphetamine reinforcement in rhesus
macaques (Odabas-Geliday et al., 2019). There are several reasons why these two studies report
conflicting results. First, each study was underpowered, using only 3 nonhuman primates, which
could somewhat limit firm conclusions regarding behavioral outcomes. Second, different 5-HT2A
drugs and/or different drug doses may have led to different results. Indeed, Pimavanserin doses
were 1.0-10 mg/kg while M100907 doses were 0.03-0.3 mg/kg (Banks et al., 2016; OdabasGeliday et al., 2019). Although the two drugs are both 5-HT2A antagonists, the drugs differ in
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receptor selectivity, with Pimavanserin only having a 40-fold selectivity for the 5-HT2A receptor
over the 5-HT2C receptor while M100907 has 100-fold selectivity for the 5-HT2A receptor over
the 5-HT2C receptor. Despite these differences, Pimavanserin and M100907 both elicit similar
behavioral effects. For instance, both Pimavanserin and M100907 have been reported to reduce
psychotic symptoms in both humans and rats (McFarland et al., 2011). Collectively, these data
suggest that blocking 5-HT2A receptors generally fails to alter psychostimulant reinforcement.
When examining results from the CPP paradigm specifically, the present findings seem
to conflict with previous research indicating that M100907 attenuates acquisition of CPP in male
and female rats (Madden et al., 2020; 2021). However, there are two important differences that
could account for these differing outcomes. First, although each of the studies used female and
male Long-Evans hooded rats, the doses of M100907 varied slightly. The previous study used an
M100907 dose range of 0.025-0.25 mg/kg (Madden et al., 2020; 2021) while the present study
used an M100907 dose range of 0.0025-0.1 mg/kg. Perhaps, a broader range of doses might alter
expression of methamphetamine-induced CPP similar to acquisition. Second, the present study
examined expression of methamphetamine-induced CPP by giving rats an acute injection of
M100907 prior to the expression test. In contrast, in Madden and colleagues’ study, rats received
M100907 prior to each of the four methamphetamine conditioning sessions. Therefore, the
effects of M100907 during the acquisition phase indicate that blocking 5-HT2A receptors either
reduces the subjective reward experience or prevents the conditioned association of the
rewarding experience with the distinct context of the CPP apparatus. The current study examined
if M100907 would also attenuate reward seeking following methamphetamine conditioning.
Therefore, it is possible that M100907 is effective at blocking the reward-environment pairing
experience, but not effective at decreasing drug seeking after this reward-environment pairing
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has already been established. However, other research examining psychostimulant seeking in rats
found that various doses of M100907 attenuate drug seeking. For example, M100907 (0.5-2.0
mg/kg) attenuates cue-induced and nicotine-primed reinstatement of extinguished nicotineseeking behavior (Fletcher et al., 2012) and M100907 (0.001-0.8 mg/kg) suppresses cue-induced
reinstatement of extinguished cocaine-seeking behavior (Nic Dhonnchadha et al., 2009). A study
establishing subthreshold doses for M100907 on drug seeking reported different outcomes
depending on the behavioral measure. For example, when examining cocaine-primed
reinstatement, the subthreshold dose of M100907 is 0.1 mg/kg, while the effective dose range of
M100907 when examining cue-induced cocaine reinstatement is 0.001 mg/kg-0.01 mg/kg
(Cunningham et al., 2013). Collectively, these data examining the effects of blocking 5-HT2A
receptors on drug-seeking behavior suggest that higher doses of M100907 may be needed to alter
expression of methamphetamine-induced CPP.
Although in the introduction we stated that chronic methamphetamine exposure causes
increased 5-HT2A receptor expression in the PFC of male rats, Hámor and colleagues note that
this may be the result of a compensatory response to initial serotonin depletion following
methamphetamine use (Hámor et al., 2018). Neurobiologically, chronic methamphetamine
exposure leads to decreased frontal cortical serotonin levels in rodents (Heal et al., 1985;
Mcfadden et al., 2013). Rats chronically administered d-amphetamine followed by a 24-hour
withdrawal period show significantly decreased 5-HT2A receptor mRNA expression in the
prefrontal, motor and cingulate cortices, while 5-HT2A receptor expression is increased in the
NAc, caudate putamen (CPu) and hippocampus (Horner et al., 2011). The authors speculate that
this may be due to the body’s compensatory response to amphetamine-induced serotonin influx,
with the decreased activation of the PFC leading to decreased activation of downstream brain
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structures such as the NAc, CPu and hippocampus. In order to compensate, this leads to an
increase in 5-HT2A receptor expression in the NAc, CPu, and hippocampus (Horner et al., 2011).
Depletion of serotonin in frontal cortical structures leads to increased impulsivity, which could
exacerbate the likelihood of relapse (Harrison et al., 1997). M100907 has been shown to increase
attentional performance and reduce impulsivity in rats (Winstanley et al., 2003). Additionally,
M100907 decreases cocaine-induced Fos protein expression in the CPu (Pockros et al., 2012).
This suggests that although there is decreased serotonin receptor expression in the PFC,
M100907 may still help attenuate methamphetamine-induced reward, given M100907s
efficaciousness at attenuating impulsivity and Fos expression. This could further explain why
Madden and colleagues saw attenuation in acquisition of methamphetamine-induced CPP.
M100907 was administered prior to methamphetamine administration, suggesting that M100907
could block the serotonergic influx caused by methamphetamine. This could make
methamphetamine less rewarding and account for the decrease in time spent on the
methamphetamine paired side of the chamber on test day. However, in the current study,
M100907 was not administered with methamphetamine; therefore, it is possible the serotonergic
system was already depleted when testing occurred. Thus, M100907 would not have any impact
on expression of methamphetamine-induced CPP, as reported in the current study. Additionally,
levels of PFC 5-HT2A receptors is critical, with a study reporting that the activity and release of
dopamine neurons in the VTA and PFC are modulated by PFC 5-HT2A receptors (Bortolozzi et
al., 2005). Although administration of a 5-HT2A receptor antagonist does not alter tonic firing
rates of VTA dopamine neurons, they do reverse the increase in phasic dopamine firing evoked
by 5-HT2A receptor agonists (Bubar & Cunningham, 2008; Pehek et al., 2006). It has also been
shown that administration of M100907 blocks psychostimulant-induced increases in dopamine
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release in the VTA (Pehek et al., 2001). Collectively, downregulation of 5-HT2A receptors
following chronic methamphetamine exposure may explain why rats in the present study did not
respond to 5-HT2A receptor antagonism and still exhibited drug-seeking behavior.
Another important receptor to consider that regulates the mesolimbic dopamine pathway
is the 5-HT2C receptor (Alex & Pehek, 2007). Indeed, 5-HT2C receptor agonists decrease basal
firing rates of VTA dopamine neurons and dopamine efflux into the NAc (Bubar &
Cunningham, 2008; De Deurwaerdère & Spampinato, 1999). Systemic administration of a 5HT2C receptor agonist results in inhibition of mesolimbic dopamine activity and suppression of
THC- and nicotine-induced CPP in rats (Ji et al., 2006; Alex and Pehek, 2007). Additionally,
systemic administration of the 5-HT2C agonist R0-60175 leads to a decrease in dopamine efflux
in the PFC and blocks stress-induced dopamine increases in the PFC (Alex and Pehek, 2007).
Importantly, the 5-HT2C agonist MK212 blocks expression of cocaine-induced CPP in male rats
(dela Cruz et al., 2009). Together, these data suggest that a combination of a 5-HT2A receptor
antagonist and a 5-HT2C receptor agonist may elicit more potent behavioral responses, in contrast
with the present study which only used one pharmacological intervention.
Due to the complexity of the serotonergic system and prominent roles of the 5-HT2A and
5-HT2C receptors, future studies should investigate a combination of pharmacotherapies,
specifically a 5-HT2C receptor agonist and 5-HT2A receptor antagonist. Studies report that
antagonizing the 5-HT2A receptor and agonizing the 5-HT2C receptor blocks the discriminative
stimulus effects of cocaine and nicotine (Bubar & Cunningham, 2008; McMahon &
Cunningham., 2001; Zaniewska et al., 2009), and administration of a 5-HT2C receptor agonist
and a 5-HT2A receptor antagonist blocks acquisition and expression of cocaine-induced CPP in
rats (dela Cruz et al., 2009). Additionally, both M100907 and the 5-HT2C receptor agonist
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MK212 synergistically attenuate cocaine-induced dopamine release and hyperlocomotion
(Pockros et al.,2012). Further, M100907 and the 5-HT2C receptor agonist WAY163909
synergistically suppress cocaine hyperactivity as well as cue- and cocaine-primed reinstatement
of cocaine seeking in rats (Cunningham et al., 2013). Acute 5-HT2C agonist (Lorcaserin)
administration decreases cocaine self-administration, while treatment with Lorcaserin plus
Pimavanserin decreases cocaine seeking in rats (Anastasio et al., 2020). Collectively, these data
suggest that combinations of pharmacotherapies targeting the 5-HT2A and 5-HT2C receptor
families could be more effective in treating both substance use disorder in general and MUD
specifically.
There is also clinical interest in using a combination of either the 5-HT2A receptor
antagonist M100907 or the 5-HT2A receptor inverse agonist Pimavanserin combined with the 5HT2C receptor agonist Lorcaserin. M100907, or Volinanserin, was recently studied in clinical
trials for treatment of insomnia and depression (clinicaltrials.gov). Pimavanserin is an FDAapproved drug for the treatment of Parkinson’s disease psychosis and is classified as a 5-HT2A
receptor inverse agonist (Friedman, 2013; Meltzer et al., 2010). Lorcaserin was previously FDAapproved for treatment of obesity (Gustafson et al., 2013). During a Phase 1 clinical trial,
Lorcaserin decreased cocaine craving in cocaine users (Johns et al., 2021). Additionally, studies
report that Lorcaserin significantly reduces cannabis self-administration and reduces cannabis
craving in humans (Arout et al., 2021), and reduces cannabis, alcohol and nicotine intake in
humans (Campbell et al., 2021). Lorcaserin may be effective at treating MUD as well, with a
study reporting that Lorcaserin reduces methamphetamine intake in rhesus macaques (Gerak et
al., 2016). Future studies should continue examining the serotonergic system in relation to
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substance use disorders, and, as previously mentioned, a combination of pharmacotherapies may
yield better outcomes and present a more efficacious route for psychostimulant use disorders.
5. Conclusion
In summary, the present results indicate that blocking 5-HT2A receptors with the inverse
agonist M100907 does not attenuate expression of methamphetamine-induced CPP, suggesting
that blocking 5-HT2A receptors does not decrease contextual-induced drug seeking for
methamphetamine. Given that M100907 reduces the reinforcing and rewarding effects of
psychostimulants, a broader dose range should be investigated for this experimental design.
Additionally, a promising direction of methamphetamine research could consist of combining 5HT2A antagonists, such as M100907 or Pimavanserin, with 5-HT2C agonists, such as Lorcaserin
(Anastasio et al., 2020; Kohut et al., 2014). This approach might result in a more effective MUD
pharmacological treatment, maximizing the effects of targeting both receptors to reduce drug
seeking while minimizing potential side effects (e.g., locomotor effects). Future research should
continue to investigate the link between the serotonergic system and its influence in
methamphetamine abuse. Previous studies have reported conflicting results with M100907
decreasing the rewarding and reinforcing effects of stimulants (Nic Dhonnchadha et al., 2009;
Fletcher et al., 2012; Madden et al., 2020; 2021), while other studies report no change in drugrelated behavior (Bubar & Cunningham, 2008; Banks et al., 2016). Replication and extension of
the present results is needed to fully clarify the ability of M100907 to alter methamphetamine
abuse-related behaviors.
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